BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24589437)

  • 1. Prospective screening for ALK: clinical features and outcome according to ALK status.
    Fallet V; Cadranel J; Doubre H; Toper C; Monnet I; Chinet T; Oliviero G; Foulon G; De Cremoux H; Vieira T; Antoine M; Wislez M
    Eur J Cancer; 2014 May; 50(7):1239-46. PubMed ID: 24589437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ALK gene fusion associated non-small cell lung cancer: automated immunostainer detection and clinicopathologic perspectives].
    Shen Q; Pan Y; Yu B; Shi S; Liu B; Xu Y; Wang Y; Xia Q; Rao Q; Lu Z; Shi Q; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):164-9. PubMed ID: 26268749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
    J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
    Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
    World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

  • 16. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
    Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
    J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
    Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
    Ren S; Hirsch FR; Varella-Garcia M; Aisner DL; Boyle T; Zhou C; Camidge DR
    J Thorac Oncol; 2014 Mar; 9(3):e21-3. PubMed ID: 24518095
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
    Yoshida A; Tsuta K; Nakamura H; Kohno T; Takahashi F; Asamura H; Sekine I; Fukayama M; Shibata T; Furuta K; Tsuda H
    Am J Surg Pathol; 2011 Aug; 35(8):1226-34. PubMed ID: 21753699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.